{"product_id":"jxr-fertility-five-forces-analysis","title":"Jinxin Fertility Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eJinxin Fertility faces moderate buyer power and regulatory pressure, while supplier leverage and substitute threats remain manageable amid rising demand for fertility services; competitive rivalry is intensifying with new clinics and tech-enabled entrants. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Jinxin Fertility’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Pharmaceutical Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJinxin Fertility depends on a few global pharma firms for IVF drugs; top suppliers (eg, Merck KGaA, Ferring Pharmaceuticals) control ~60–70% of key gonadotropin and antagonist supply, giving them strong bargaining power.\u003c\/p\u003e\n\u003cp\u003eThese products are patent-protected and heavily regulated, so price hikes or a 10–20% supply disruption — like the 2023 global gonadotropin shortage that raised prices ~15% — would directly widen COGS and compress margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScarcity of Highly Skilled Medical Professionals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe supply of experienced embryologists and reproductive physicians is scarce versus rising demand: China had ~50,000 ART cycles per million women in 2023 and clinics report vacancy rates near 18% for senior staff. These specialists command high pay and leverage—median senior embryologist compensation rose ~22% YoY to ¥520k in 2024—forcing Jinxin to invest in retention packages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Laboratory Equipment Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialized incubators and genetic screening tools used in assisted reproductive services come from a handful of high-tech firms, giving suppliers concentrated bargaining power; global IVF device market leaders hold roughly 60% share as of 2024.\u003c\/p\u003e\n\u003cp\u003eHigh technical complexity and certified maintenance create steep switching costs—equipment replacement can cost $200k–$1M per lab unit and require 2–6 months recertification. \u003c\/p\u003e\n\u003cp\u003eJinxin’s throughput and IVF cycle capacity depend on suppliers’ maintenance windows and upgrade cadences; missed service windows can cut lab utilization by 10–20% and raise per-cycle costs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Genetic Testing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs genetic screening becomes standard in ART, third-party genomic labs wield growing supplier power; industry reports show global genetic testing revenue hit $12.6B in 2024, up 8% vs 2023, concentrating pricing power among top biotech partners.\u003c\/p\u003e\n\u003cp\u003eJinxin retains in-house screening but outsources high-volume or proprietary tests; exclusivity in diagnostic algorithms lets vendors set premiums—outsourced panel costs can be 30–70% higher than basic internal tests.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 market size: $12.6B\u003c\/li\u003e\n\u003cli\u003eOutsourced tests cost +30–70%\u003c\/li\u003e\n\u003cli\u003eTop vendors control proprietary databases\u003c\/li\u003e\n\u003cli\u003eJinxin uses mix of internal and partner labs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal Estate and Facility Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpoperating premium fertility centers in tier-one cities like beijing shanghai new york and san francisco demands medical-grade real estate prime zones giving landlords strong leverage because surgical need specific hvac waste emergency access standards china hospital-adjacent rents rose annually us healthcare major metros averaged long-term leases years are essential to lock avoid displacement risk as build-out costs often exceed for or-capable space.\u003e \n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh landlord leverage: premium location + strict zoning\u003c\/li\u003e\n\u003cli\u003eChina rents up 6–9% (2024); US healthcare rents $35–$60\/sqft\/yr (2024)\u003c\/li\u003e\n\u003cli\u003eLong-term 10+ year leases mitigate displacement\u003c\/li\u003e\n\u003cli\u003eOR build-outs ≈ $1,200+\/sqft, raising switching costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/poperating\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier dominance, price shocks and rising labor\/device costs squeeze IVF margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers wield strong power: top pharma (eg, Merck KGaA, Ferring) control ~60–70% of gonadotropins; 2023 shortage raised prices ~15%, squeezing margins; senior embryologist pay rose ~22% to ¥520k in 2024, driving higher labor costs; IVF device vendors hold ~60% market share and lab units cost $200k–$1M with 2–6 month recertification, raising switching costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2023–24)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop pharma share\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice shock (2023)\u003c\/td\u003e\n\u003ctd\u003e+15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSenior embryologist pay\u003c\/td\u003e\n\u003ctd\u003e¥520k, +22% YoY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice market share (leaders)\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab unit cost\u003c\/td\u003e\n\u003ctd\u003e$200k–$1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Jinxin Fertility highlighting competitive rivalry, buyer\/supplier power, threat of new entrants and substitutes, and regulatory\/disruptive pressures that shape pricing, profitability, and strategic defenses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Jinxin Fertility—clarifies competitive threats and bargaining dynamics at a glance to speed strategic choices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Information Accessibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients in 2025 access aggregated IVF success-rate dashboards and clinic-level outcome registries—China’s online platforms show clinic live-birth rates and price comparisons, and 68% of fertility seekers consult three+ sites before choosing a provider. This transparency lets customers shop and push down weak performers, so Jinxin must sustain above-market success metrics (e.g., \u0026gt;45% live-birth per cycle target) to keep pricing power and market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity of the Middle Class\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMiddle-class patients treat fertility care as necessary but cost-sensitive; average IVF out-of-pocket in China was about RMB 60,000–100,000 (2024 studies), so Jinxin faces price pressure.\u003c\/p\u003e\n\u003cp\u003eMany compare Jinxin’s private fees with subsidized public hospital rates, which can be 30–60% lower, reducing willingness to pay.\u003c\/p\u003e\n\u003cp\u003eTo compete, Jinxin often must offer installment financing, bundled treatment packages, or success-fee models to expand uptake among middle-income couples.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs Between Private Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn the US mature market, easy transfer of medical records and frozen embryos raises buyer power—patients often move clinics with minimal friction, boosting churn risk; a 2023 ASRM report found 18% of patients switched providers during treatment. Clinics now compete on concierge services and patient experience, where a 10–15% revenue uplift is seen for high-touch models. Jinxin must prioritize personalized care, dedicated care teams, and post-cycle support to lock loyalty and cut switching.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Patient Advocacy and Support Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganized patient communities and forums drive reputation: a 2024 survey found 62% of Chinese IVF patients rely on online reviews before choosing a clinic, so collective sentiment can swing demand quickly.\u003c\/p\u003e\n\u003cp\u003eNegative threads correlate with faster patient churn—clinics reporting public complaints saw up to a 18% drop in monthly new bookings within 30 days in 2023.\u003c\/p\u003e\n\u003cp\u003eJinxin must engage proactively—monitor forums, respond within 72 hours, and publish patient outcomes to stabilize perception and protect acquisition.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of patients use online reviews (2024 survey)\u003c\/li\u003e\n\u003cli\u003e18% drop in new bookings after public complaints (2023 data)\u003c\/li\u003e\n\u003cli\u003eTarget response time: ≤72 hours\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Government Reimbursement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs China widened insurance coverage for assisted reproductive technology in 2024, state payers gained leverage, allowing negotiated unit rates down 8–15% in pilot cities, which shifts bargaining power to institutional buyers.\u003c\/p\u003e\n\u003cp\u003eSuch standardized pricing compresses private clinics’ gross margins—Jinxin reported 2023 gross margin ~41%; a 10% rate cut could lower it toward ~36% unless costs fall.\u003c\/p\u003e\n\u003cp\u003eJinxin must redesign contracts, offer bundled care, and push volume or ancillary services to preserve profitability while complying with public reimbursement rules.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 pilot cuts 8–15%\u003c\/li\u003e\n\u003cli\u003eJinxin 2023 gross margin ~41%\u003c\/li\u003e\n\u003cli\u003e10% rate cut → ~5pp margin hit (quick math)\u003c\/li\u003e\n\u003cli\u003eMitigations: bundled pricing, ancillaries, cost control\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJinxin must hit \u0026gt;45% live-births and cut prices to survive payer rate cuts and savvy patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients have high leverage: 68% consult 3+ sites and 62% read reviews (2024), so clinic choice is outcome- and price-driven; Jinxin must sustain \u0026gt;45% live-birth\/cycle and competitive pricing (RMB 60k–100k typical) to retain share. Payer leverage rose after 2024 pilots cut reimbursed rates 8–15%, threatening Jinxin’s 2023 ~41% gross margin (≈5pp hit from 10% cut) and forcing bundling, ancillaries, and financing. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients consulting 3+ sites\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUse online reviews\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical IVF OOP (China)\u003c\/td\u003e\n\u003ctd\u003eRMB 60,000–100,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 pilot rate cuts\u003c\/td\u003e\n\u003ctd\u003e8–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJinxin gross margin (2023)\u003c\/td\u003e\n\u003ctd\u003e~41%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated margin hit (10% cut)\u003c\/td\u003e\n\u003ctd\u003e~5pp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eJinxin Fertility Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of Jinxin Fertility you’ll receive immediately after purchase—no surprises, no placeholders. The document displayed here is the actual, fully formatted file ready for download and use the moment you buy. You’re viewing the complete, professionally written analysis—precisely the same deliverable available to you instantly after payment. No mockups, no samples; what you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746681893241,"sku":"jxr-fertility-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/jxr-fertility-five-forces-analysis.png?v=1772190904","url":"https:\/\/growthsharematrix.com\/products\/jxr-fertility-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}